Microglia depletion and repopulation therapy represents an emerging therapeutic strategy for neurodegenerative diseases that aims to eliminate disease-associated microglia and replace them with healthy, functionally competent cells. This approach leverages the unique capacity of the brain's innate immune system to regenerate following targeted depletion, potentially resetting the neuroinflammatory environment in conditions like Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1].
The therapeutic rationale stems from growing evidence that chronic neuroinflammation driven by dysfunctional microglia contributes substantially to neurodegeneration. Rather than attempting to modulate microglial activity pharmacologically, this strategy takes a more fundamental approach—complete depletion followed by repopulation with cells that may better support brain homeostasis[2].
Colony-stimulating factor 1 receptor (CSF1R) is a critical survival factor for microglia. CSF1R inhibitors work by blocking the receptor's signaling, leading to apoptosis of most resident microglia in the brain. Two compounds have been extensively used in preclinical research:
PLX5622 (Plexxikon): A highly selective CSF1R antagonist that achieves rapid and sustained microglia depletion when administered continuously. Studies show approximately 95% depletion of Iba1+ microglia within 21 days of treatment[3].
PLX3397 (Pexidartinib): Originally developed for cancer therapy, this CSF1R/FLT3/c-KIT inhibitor has been used in several neurodegeneration studies. While less selective than PLX5622, it effectively depletes microglia[4].
The selectivity for microglia arises from their unique dependence on CSF1R signaling for survival, compared to other brain cell types.
Microglia depletion follows a characteristic pattern:
Following CSF1R inhibitor withdrawal, microglia spontaneously repopulate the brain through local proliferation of surviving cells and potentially from bone marrow-derived precursors. This repopulation:
For more complete replacement, bone marrow transplantation (BMT) can be combined with whole-body irradiation to enable donor-derived microglia-like cells to engraft in the brain. This approach:
| Aspect | Spontaneous Repopulation | Bone Marrow Transplant |
|---|---|---|
| Speed | 2-3 weeks | 4-8 weeks |
| Cell source | Resident progenitors | Bone marrow |
| Safety | High | Moderate-High |
| Clinical readiness | High | Low |
The timing of microglia depletion relative to disease progression significantly impacts therapeutic outcomes:
In AD models, early depletion (before significant amyloid deposition) prevents the establishment of disease-associated microglial transcriptional programs and reduces later pathology[6].
Depletion during established pathology can reverse some disease-associated signatures and improve cognitive function in mouse models[7].
Depletion in end-stage disease shows more modest benefits, suggesting that timing is critical for maximal efficacy.
TREM2 (Triggering receptor expressed on myeloid cells 2) is a receptor on microglia that recognizes amyloid and other disease-associated signals. TREM2 variants represent major genetic risk factors for AD. Combining microglia depletion with TREM2-targeted approaches shows promise:
Studies combining PLX5622 with TREM2 agonistic antibodies show:
In 5xFAD and APP/PS1 mouse models, microglia depletion and repopulation:
Key studies include Huang et al. (2022) demonstrating that PLX5622 treatment of 5xFAD mice improved performance on multiple cognitive tests and reduced hippocampal amyloid[9].
In alpha-synuclein transgenic models (e.g., M83, ASO):
In SOD1-G93A mice:
Microglia play crucial roles in immune surveillance and pathogen defense in the brain. Concerns include:
Microglia depletion can affect BBB integrity:
CSF1R inhibition affects peripheral macrophages, potentially causing:
Long-term studies in primates show:
No microglia depletion therapy has been approved for neurodegenerative diseases. However:
PLX5622: Has been used in over 20 clinical trials for various conditions (primarily cancer), establishing safety data. Planning for AD trials is underway.
PLX3397: FDA-approved for tenosynovial giant cell tumor. Safety profile established in thousands of patients.
Hansen DV, et al. Microglia development in the normal brain and in neurodegeneration. 2022. ↩︎
Sosna J, et al. Early long-term depletion of microglia leads to Amyloid-beta accumulation and cognitive deficits. 2018. ↩︎
Dagher NN, et al. Colony-stimulating factor 1 receptor (CSF1R) blockade attenuates neurodegeneration and improves behavioral outcomes in a mouse model of Alzheimer's disease. 2015. ↩︎
Mok S, et al. Inhibition of CSF1R reduces neuroinflammation and improves cognition in an Alzheimer's disease mouse model. 2018. ↩︎
Bruttger J, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the adult mammalian brain. 2015. ↩︎
Shi Q, et al. Microglia depletion early in life and cognitive function in adult mice. 2021. ↩︎
Xiang X, et al. Targeting microglia for Alzheimer's disease therapy. 2023. ↩︎
Schelle J, et al. TREM2 activation and microglia depletion after amyloid reduction. 2023. ↩︎
Huang Y, et al. Microglia depletion improves outcomes after amyloid reduction in 5xFAD mice. 2022. ↩︎